1. Scrip
  2. >>Focus On Asia

Japan To Reimburse Zolgensma – But At Lower Price Than US

NHI Scheme Grants Coverage

 
• By Ian Haydock

Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.

Gene therapy
Gene Therapy Zolgensma Sets Price Record In Japan • Source: Shutterstock

Japan’s regulatory authorities have decided to grant Novartis AG/AveXis Inc.’s gene therapy Zolgensma (onasemnogene abeparvovec) reimbursement under the national health insurance scheme, marking a watershed in drug pricing in the country, although the annualized cost will be less than many other big-selling products.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia

NIH Funding Cut Left Less Money On R&D Table, Tariffs Would Add To Woes: Aragen’s CEO

 
• By Vibha Ravi

Funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, GCC partnerships and talks with the Indian government to solve intellectual property challenges are discussed in an interview with Aragen’s CEO, who is also keenly watching the Trump administration’s moves on pharma tariffs

Akeso Explains Ivonescimab Prelim OS Data After Investors’ Negative Reactions

 
• By Dexter Jie Yan

Akeso explains the circumstances behind the release of preliminary overall survival data from a head-to-head Phase III trial with ivonescimab in lung cancer, which some investors viewed as disappointing.

Novotech CEO On Flexible Trial Solutions Amid Tariff, Geopolitical Tensions

 
• By Anju Ghangurde

Novotech's CEO talks about rising interest for trials in regions with “regulatory agility” and “strategic insulation” from geopolitical complexity, especially among emerging and mid-sized biotech sponsors. Operational "reassessment” among some sponsors on exposure to China-based CROs/CRDMOs is another area he discussed.